Indication
B-Cell Malignancies
3 clinical trials
10 products
Product
ParsaclisibProduct
ItacitinibClinical trial
A Phase 1/2, Open-Label, Dose Escalation, Safety and Tolerability Study of INCB050465 and Iitacitinib in Subjects With Previously Treated B-Cell Malignancies (CITADEL-101)Status: Completed, Estimated PCD: 2021-04-12
Product
IfosfamideProduct
EtoposideProduct
RituximabProduct
CarboplatinProduct
TT-01488Clinical trial
A Phase I, Multicenter, Open Label, and Dose-Escalation Study of TT-01488, Administered Orally in Adult Patients With B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2026-10-31
Clinical trial
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465)Status: Recruiting, Estimated PCD: 2024-09-30
Product
Parsaclisib + ItacitinibProduct
Parsaclisib + RuxolitinibProduct
Parsaclisib + Ibrutinib